Mitochondria Targeted Peptides Protect Against 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Neurotoxicity

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Antioxidants and Redox Signaling

• Publication date

  2009-08-10

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1089/ars.2009.2445PMID 19203217PMCID PMC2819801
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mitochondria-Targeted Cytoprotective Peptides for Ischemia–Reperfusion Injury

  2008influential reference
• Do Mitochondriotropic Antioxidants Prevent Chlorinative Stress-Induced Mitochondrial and Cellular Injury?

  2008influential reference
• Anaerobic Glycolysis Protection against 1-Methy-4-Phenylpyridinium (MPP+) Toxicity in C6 Glioma Cells

  2007cited by this paper
• Additive neuroprotective effects of creatine and a cyclooxygenase 2 inhibitor against dopamine depletion in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson’s disease

  2007cited by this paper
• A Novel Cell-permeable Antioxidant Peptide, SS31, Attenuates Ischemic Brain Injury by Down-regulating CD36*

  2007cited by this paper
• Potent mitochondria-targeted peptides reduce myocardial infarction in rats

  2007cited by this paper
• Cell-permeable peptide antioxidants as a novel therapeutic approach in a mouse model of amyotrophic lateral sclerosis.

  2006influential reference
• Differential Involvement of Mitochondrial Permeability Transition in Cytotoxicity of 1-Methyl-4-Phenylpyridinium and 6-Hydroxydopamine

  2006cited by this paper
• The genetics of Parkinson disease: implications for neurological care

  2006cited by this paper
• Depletion of cardiolipin and cytochrome c during ischemia increases hydrogen peroxide production from the electron transport chain.

  2006cited by this paper
• Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases

  2006cited by this paper
• Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis.

  2005cited by this paper
• A novel azulenyl nitrone antioxidant protects against MPTP and 3-nitropropionic acid neurotoxicities.

  2005cited by this paper
• Mitochondria-targeted peptide prevents mitochondrial depolarization and apoptosis induced by tert-butyl hydroperoxide in neuronal cell lines.

  2005influential reference
• Melatonin protects against MPTP/MPP+‐induced mitochondrial DNA oxidative damage in vivo and in vitro

  2005cited by this paper
• MPTP as a Mitochondrial Neurotoxic Model of Parkinson's Disease

  2004cited by this paper
• Lack of evidence of direct mitochondrial involvement in the neuroprotective effect of minocycline.

  2004cited by this paper
• Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease

  2004cited by this paper
• Cell-permeable Peptide Antioxidants Targeted to Inner Mitochondrial Membrane inhibit Mitochondrial Swelling, Oxidative Cell Death, and Reperfusion Injury*

  2004influential reference
• The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization

  2004cited by this paper
• Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease

  2003cited by this paper
• Coenzyme Q10 in neurodegenerative diseases.

  2003cited by this paper
• Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death.

  2003cited by this paper
• Transcellular Transport of a Highly Polar 3+ Net Charge Opioid Tetrapeptide

  2003cited by this paper
• Role of reactive oxygen species and cardiolipin in the release of cytochrome c from mitochondria

  2003cited by this paper
• Minocycline enhances MPTP toxicity to dopaminergic neurons

  2003cited by this paper
• Rapid reduction of ATP synthesis and lack of free radical formation by MPP+ in rat brain synaptosomes and mitochondria.

  2003cited by this paper
• The rotenone model of Parkinson's disease: genes, environment and mitochondria.

  2003influential reference
• Prevention of Mitochondrial Oxidative Damage Using Targeted Antioxidants

  2002cited by this paper
• Blockade of Microglial Activation Is Neuroprotective in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model of Parkinson Disease

  2002cited by this paper
• Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice

  2002cited by this paper
• An In Vitro Model of Parkinson's Disease: Linking Mitochondrial Impairment to Altered α-Synuclein Metabolism and Oxidative Damage

  2002influential reference
• Chronic systemic pesticide exposure reproduces features of Parkinson's disease

  2000cited by this paper
• Neuroprotection and Neuronal Differentiation Studies Using Substantia Nigra Dopaminergic Cells Derived from Transgenic Mouse Embryos

  1999cited by this paper
• The parkinsonian neurotoxin MPP+ opens the mitochondrial permeability transition pore and releases cytochrome c in isolated mitochondria via an oxidative mechanism.

  1999influential reference
• Loss of molecular interaction between cytochrome c and cardiolipin due to lipid peroxidation.

  1999cited by this paper
• Inactivation of Human Manganese-superoxide Dismutase by Peroxynitrite Is Caused by Exclusive Nitration of Tyrosine 34 to 3-Nitrotyrosine*

  1998cited by this paper
• Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3,tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice.

  1998cited by this paper
• Azulenyl nitrone spin traps protect against MPTP neurotoxicity.

  1998cited by this paper
• Two mechanisms by which ATP depletion potentiates induction of the mitochondrial permeability transition.

  1997cited by this paper
• Origin and functional consequences of the complex I defect in Parkinson's disease

  1996cited by this paper
• Low platelet mitochondrial complex I and complex II/III activity in early untreated parkinson's disease

  1995cited by this paper
• Inhibition of Neuronal Nitric Oxide Synthase by 7‐Nitroindazole Protects Against MPTP‐Induced Neurotoxicity in Mice

  1995cited by this paper
• Effects of 1‐Methyl‐4‐Phenylpyridinium on Isolated Rat Brain Mitochondria: Evidence for a Primary Involvement of Energy Depletion

  1994cited by this paper
• 1-methyl-4-phenylpyridinium (MPP[+]) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles

  1993influential reference
• MPP+ and MPDP+ induced oxygen radical formation with mitochondrial enzymes.

  1993influential reference
• Rapid ATP Loss Caused by 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine in Mouse Brain

  1991cited by this paper
• 1-Methyl-4-phenylpyridinium (MPP+) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles.

  1990cited by this paper
• Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine.

  1985cited by this paper

• Pharmaceutical Roots to Mitochondrial Routes: Targeting Neurodegeneration

  2026cites this paper
• New Insights on Mitochondria-Targeted Neurological Drugs

  2026cites this paper
• Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential

  2025cites this paper
• Mitochondrial Dynamics in Neurodegenerative Diseases: Research Hotspots and Trends from 2005 to 2025.

  2025cites this paper
• Cardiolipin and mitochondrial membrane integrity in neurodegeneration: insights from α-synuclein-driven Parkinson’s disease

  2025cites this paper
• Algal and Fungal Antioxidants Alleviate Oxidative Stress‐Induced Reproductive Defects

  2025cites this paper
• Mitophagy in Alzheimer's disease and other metabolic disorders: a focus on mitochondrial-targeted therapeutics.

  2025cites this paper
• SS-31: A promising therapeutic agent against bleomycin-induced pulmonary fibrosis in Mice

  2025cites this paper
• Targeting Mitochondrial Dysfunction and Reactive Oxygen Species for Neurodegenerative Disease Treatment

  2024cites this paper
• Mitochondria-targeted nanotherapeutics: A new Frontier in neurodegenerative disease treatment.

  2024cites this paper
• Safeguarding the brain from oxidative damage.

  2024cites this paper
• Signaling Pathways Concerning Mitochondrial Dysfunction: Implications in Neurodegeneration and Possible Molecular Targets

  2024cites this paper
• From mitochondrial dysfunction to neuroinflammation in Parkinson's disease: Pathogenesis and mitochondrial therapeutic approaches.

  2024cites this paper
• Targeting mitochondria with small molecules: A promising strategy for combating Parkinson's disease.

  2024cites this paper
• Toxic interactions between dopamine, α-synuclein, monoamine oxidase, and genes in mitochondria of Parkinson’s disease

  2024cites this paper
• Intracellular delivery of Parkin-RING0-based fragments corrects Parkin-induced mitochondrial dysfunction through interaction with SLP-2

  2024cites this paper
• Mito-metformin protects against mitochondrial dysfunction and dopaminergic neuronal degeneration by activating upstream PKD1 signaling in cell culture and MitoPark animal models of Parkinson’s disease

  2024cites this paper
• Mitochondria-targeted reactive oxygen species blockor SS-31 blocks hepatic stellate cell activation and alleviates hepatic fibrosis by regulating NLRP3 inflammasomes.

  2024cites this paper
• The Role of Cardiolipin in Mitochondrial Function and Neurodegenerative Diseases

  2024cites this paper
• Therapeutic Peptide SS-31 Modulates Membrane Binding and Aggregation of α-Synuclein and Restores Impaired Mitochondrial Function

  2024cites this paper
• On the Antioxidant Effect of SS-20 Tetrapeptide on Mitochondria and Cells

  2024cites this paper
• Temporal evolution of the heart failure phenotype in Barth syndrome and treatment with elamipretide.

  2023cites this paper
• Interactions of amyloidogenic proteins with mitochondrial protein import machinery in aging-related neurodegenerative diseases

  2023cites this paper
• Current perspectives of mitochondria-targeted antioxidants in cancer prevention and treatment

  2023cites this paper
• Targeting Mitochondrial Oxidative Stress as a Strategy to Treat Aging and Age-Related Diseases

  2023cites this paper
• SS-31 as a Mitochondrial Protectant in the Treatment of Tendinopathy

  2022cites this paper
• Structure-activity relationships of mitochondria-targeted tetrapeptide pharmacological compounds

  2022cites this paper
• Mitochondria research and neurodegenerative diseases: on the track to understanding the biological world of high complexity.

  2022cites this paper
• Targeting mitochondrial bioenergetics as a promising therapeutic strategy in metabolic and neurodegenerative diseases

  2022cites this paper
• Contributions and Limitations of Mitochondria-Targeted and Non-Targeted Antioxidants in the Treatment of Parkinsonism: an Updated Review

  2022cites this paper
• Site-specific mitochondrial dysfunction in neurodegeneration.

  2022cites this paper
• Effect of mitochondrial‐targeted antioxidants on glycaemic control, cardiovascular health, and oxidative stress in humans: A systematic review and meta‐analysis of randomized controlled trials

  2022cites this paper
• SS31 Ameliorates Podocyte Injury via Inhibiting OMA1-Mediated Hydrolysis of OPA1 in Diabetic Kidney Disease

  2022cites this paper
• Neuroprotective Effects of a Small Mitochondrially-Targeted Tetrapeptide Elamipretide in Neurodegeneration

  2022cites this paper
• SS-31 Improves Cognitive Function in Sepsis-Associated Encephalopathy by Inhibiting the Drp1-NLRP3 Inflammasome Activation

  2022cites this paper
• Redox Modulation of Mitochondrial Proteins in the Neurotoxicant Models of Parkinson's Disease

  2022cites this paper
• Antioxidant Therapeutic Strategies in Neurodegenerative Diseases

  2022cites this paper
• Targeting Mitochondria and Redox Dyshomeostasis in Brain Ageing: An Update

  2021cites this paper
• Autophagy-Lysosomal Pathway as Potential Therapeutic Target in Parkinson’s Disease

  2021cites this paper
• Structure-Activity Relationships in the Design of Mitochondria-Targeted Peptide Therapeutics

  2021cites this paper
• Interplay between cardiolipin and plasmalogens in Barth syndrome

  2021cites this paper
• Elamipretide for Barth syndrome cardiomyopathy: gradual rebuilding of a failed power grid

  2021cites this paper
• Mitochondrial dysfunction in metabolic disorders

  2021cites this paper
• SS-31 Protects Liver from Ischemia-Reperfusion Injury via Modulating Macrophage Polarization

  2021cites this paper
• Whether short peptides are good candidates for future neuroprotective therapeutics?

  2021cites this paper
• Targeting Mitochondria by SS-31 Ameliorates the Whole Body Energy Status in Cancer- and Chemotherapy-Induced Cachexia

  2021cites this paper
• Recurrent non-severe hypoglycemia aggravates cognitive decline in diabetes and induces mitochondrial dysfunction in cultured astrocytes.

  2021cites this paper
• Barth syndrome cardiomyopathy: targeting the mitochondria with elamipretide

  2020cites this paper
• The mitochondrial-targeted peptide SBT-20 ameliorates inflammation and oxidative stress in chronic renal failure

  2020cites this paper
• Reduction of elevated proton leak rejuvenates mitochondria in the aged cardiomyocyte

  2020cites this paper
• Cationic Arginine-Rich Peptides (CARPs): A Novel Class of Neuroprotective Agents With a Multimodal Mechanism of Action

  2020cites this paper
• Mitochondrial biogenesis as a therapeutic target for traumatic and neurodegenerative CNS diseases.

  2020cites this paper
• The Association Between Myocardial Strain and Frailty in the Cardiovascular Health Study

  2020cites this paper
• Mitochondrial targeted therapy with elamipretide (MTP-131) as an adjunct to tumor necrosis factor inhibition for traumatic optic neuropathy in the acute setting.

  2020cites this paper
• Mitochondrial Dysfunction In Aging Related Diseases; potential mitochondrial based therapeutics in Sarcopenia and Age-related Macular Degeneration.

  2020cites this paper
• Mitochondria-Targeted Antioxidants: A Step towards Disease Treatment

  2020cites this paper
• Safety, pharmacokinetics and pharmacodynamics of SBT‐020 in patients with early stage Huntington's disease, a 2‐part study

  2020influential citation
• Metabolic Alterations Caused by Defective Cardiolipin Remodeling in Inherited Cardiomyopathies

  2020cites this paper
• Riding the tiger – physiological and pathological effects of superoxide and hydrogen peroxide generated in the mitochondrial matrix

  2020cites this paper
• Elucidating Critical Proteinopathic Mechanisms and Potential Drug Targets in Neurodegeneration

  2019cites this paper
• Neurodegenerative Diseases and Their Therapeutic Approaches

  2019cites this paper
• Mitochondrial dysfunction and oxidative stress in induced pluripotent stem cell models of Parkinson's disease

  2019cites this paper
• Mitochondrial dynamics, a key executioner in neurodegenerative diseases.

  2019cites this paper
• Multifunctional radical quenchers as potential therapeutic agents for the treatment of mitochondrial dysfunction.

  2019cites this paper
• Improving mitochondrial function with SS-31 reverses age-related redox stress and improves exercise tolerance in aged mice.

  2019cites this paper
• Emerging concepts of mitochondrial dysfunction in Parkinson's disease progression: Pathogenic and therapeutic implications.

  2019cites this paper
• Mitochondrial dysfunction in neurodegenerative diseases and drug targets via apoptotic signaling.

  2019cites this paper
• Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice

  2019cites this paper
• Mitochondria and Reactive Oxygen Species in Aging and Age-Related Diseases.

  2018cites this paper
• Interventions for age-related diseases

  2018cites this paper
• Abnormalities of Mitochondrial Dynamics in the Failing Heart: Normalization Following Long-Term Therapy with Elamipretide

  2018cites this paper
• Mitochondrial abnormalities in Parkinson's disease and Alzheimer's disease: can mitochondria be targeted therapeutically?

  2018cites this paper
• Vinyl chloride enhances diet-induced liver injury via metabolic dyshomeostasis : critical role of mitochondria.

  2018cites this paper
• Mitochondria-targeting and cell-penetrating peptides-co-modified HPMA copolymers for enhancing therapeutic efficacy of α-tocopheryl succinate.

  2018cites this paper
• The antioxidant peptide SS31 prevents oxidative stress, downregulates CD36 and improves renal function in diabetic nephropathy

  2018cites this paper
• Protective Effect of a Mitochondria-Targeted Peptide against the Development of Chemotherapy-Induced Peripheral Neuropathy in Mice.

  2018cites this paper
• Role of phytotherapy in diabetic neuropathy and neurodegeneration: from pathogenesis to treatment

  2018cites this paper
• Synthetic Investigation of Natural Products Causing Dopaminergic Neurodegeneration

  2018cites this paper
• The mitochondrial antioxidant SS-31 increases SIRT1 levels and ameliorates inflammation, oxidative stress and leukocyte-endothelium interactions in type 2 diabetes

  2018cites this paper
• Mitochondria-targeted Antioxidants as a Prospective Therapeutic Strategy for Multiple Sclerosis.

  2017cites this paper
• Chronic administration of mitochondrion-targeted peptide SS-31 prevents atherosclerotic development in ApoE knockout mice fed Western diet

  2017cites this paper
• Antioxidant modulation in restoring mitochondrial function in neurodegeneration

  2017cites this paper
• Peptide SS-31 upregulates frataxin expression and improves the quality of mitochondria: implications in the treatment of Friedreich ataxia

  2017cites this paper
• The mitochondrial-targeted peptide, SS-31, improves glomerular architecture in mice of advanced age.

  2017cites this paper
• Mitochondrial-Targeted Catalase: Extended Longevity and the Roles in Various Disease Models.

  2017cites this paper
• Mitochondrial Dysfunction and Biogenesis in Neurodegenerative diseases: Pathogenesis and Treatment

  2017cites this paper
• Reinforcing mitochondrial functions in aging brain: An insight into Parkinson's disease therapeutics.

  2017cites this paper
• The entangled ER-mitochondrial axis as a potential therapeutic strategy in neurodegeneration: A tangled duo unchained.

  2016cites this paper
• Antioxidants and Redox-Based Therapeutics in Parkinson’s Disease

  2016cites this paper
• Oxidative Stress and Mitochondrial Dysfunction in Huntington’s and Other Neurodegenerative Diseases

  2016cites this paper
• Translational drug discovery approaches targeting the PKD1 signaling in Parkinson's disease

  2016cites this paper
• Mitochondrial Therapeutic Approaches in Parkinson’s Disease

  2016cites this paper
• The effects of exposure to the environmental neurotoxicant manganese on α-synuclein and its cell-to-cell transmission via exosomes

  2016cites this paper
• The C-ETS2-TFEB Axis Promotes Neuron Survival under Oxidative Stress by Regulating Lysosome Activity

  2016cites this paper
• Echinacoside Protects Against MPP+-Induced Neuronal Apoptosis via ROS/ATF3/CHOP Pathway Regulation

  2016cites this paper
• Mitochondria-Targeted Antioxidants: Future Perspectives in Kidney Ischemia Reperfusion Injury

  2016cites this paper
• BDNF pathway is involved in the protective effects of SS-31 on isoflurane-induced cognitive deficits in aging mice.

  2016cites this paper
• Systematic literature review on Parkinson's disease and Childhood Leukaemia and mode of actions for pesticides

  2016cites this paper
• Mitochondrial Mechanisms of Degeneration and Repair in Parkinson's Disease

  2016cites this paper
• Neuroprotective Effect of Coptis chinensis in MPP[Formula: see text] and MPTP-Induced Parkinson's Disease Models.

  2016cites this paper